A Phase 1 interventional study of HS-10382 in Healthy Volunteers, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The high-fat meal food effect part adopts a single-center, randomized, open-label, two-sequence, two-period, two-way crossover dosing design. Based on the results of the high-fat meal food effect trial, the sponsor and the principal investigator will comprehensively analyze and determine whether a low-fat meal food effect trial needs to be conducted.
This is a single-center, randomized, open-label, two-sequence, two-period, two-way crossover dosing design. A total of 16 participants are planned to be enrolled in each part. Eligible participants will be randomly assigned at a 1:1 ratio into two dosing sequence groups: Group 1 (A-B) and Group 2 (B-A) (A = fasting administration, B = postprandial administration), with 8 participants in each group. Enrolled participants will be admitted to the Phase I clinical trial unit on Day -1 and fast for at least 10 h before dosing. On the morning of the dosing day, a blank blood sample will be collected, after which participants will receive a single oral dose of HS-10382 tablets 160 mg under fasting conditions or after a high-fat/ low-fat meal according to their assigned dosing sequence group. Crossover dosing will be performed after a 7-day interval. The drug will be administered with approximately 240 mL of water. Water intake will be prohibited within 1 h before and after dosing (except for the water used for dosing and beverages included in the meal), and food intake will be prohibited within 4 h after dosing.
Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On the morning of the dosing day, a blank blood sample will be collected, after which participants will receive a single oral dose of HS-10382 tablets 160 mg under fasting conditions or after a high-fat/ low-fat meal according to their assigned dosing sequence group.
Drug: HS-10382
On the morning of the dosing day, a blank blood sample will be collected, after which participants will receive a single oral dose of HS-10382 tablets 160 mg under fasting conditions or after a high-fat/ low-fat meal according to their assigned dosing sequence group.
Drug: HS-10382
Drug: HS-10382 Comes in 40 mg tablets and taken orally
Evaluation of PK parameters of HS-10382: Cmax
To evaluate the Cmax of HS-10382 following fasting or fed administration
Time frame: 96 hours after administration of HS-10382
Evaluation of PK parameters of HS-10382: AUC0-t
To evaluate the AUC0-t of HS-10382 following fasting or fed administration
Time frame: 96 hours after administration of HS-10382
Evaluation of PK parameters of HS-10382: AUC0-∞
To evaluate the AUC0-∞ of HS-10382 following fasting or fed administration
Time frame: 96 hours after administration of HS-10382
Evaluation of PK parameters of HS-10382: Tmax
To evaluate the Tmax of HS-10382 following fasting or fed administration
Time frame: 96 hours after administration of HS-10382
Evaluation of PK parameters of HS-10382: tlag
To evaluate the tlag of HS-10382 following fasting or fed administration
Time frame: 96 hours after administration of HS-10382
Evaluation of PK parameters of HS-10382: t1/2z
To evaluate the t1/2z of HS-10382 following fasting or fed administration
Time frame: 96 hours after administration of HS-10382
Evaluation of PK parameters of HS-10382: λz
To evaluate the λz of HS-10382 following fasting or fed administration
Time frame: 96 hours after administration of HS-10382
Evaluation of PK parameters of HS-10382: CL/F
To evaluate the CL/F of HS-10382 following fasting or fed administration
Time frame: 96 hours after administration of HS-10382
Evaluation of PK parameters of HS-10382: Vz/F
To evaluate the Vz/F of HS-10382 following fasting or fed administration
Time frame: 96 hours after administration of HS-10382
Evaluation of PK parameters of HS-10382: MRT
To evaluate the MRT of HS-10382 following fasting or fed administration
Time frame: 96 hours after administration of HS-10382
Adverse events
To evaluate the vital signs of HS-10382 following fasting or fed administration
Time frame: Up to end of the study, approximately 1 month.
vital signs (blood pressure)
To evaluate the vital signs(blood pressure) of HS-10382 following fasting or fed administration
Time frame: Up to end of the study, approximately 1 month
vital signs (Pulse)
To evaluate the vital signs(Pulse) of HS-10382 following fasting or fed administration
Time frame: Up to end of the study, approximately 1 month
vital signs (body temperature)
To evaluate the vital signs(body temperature) of HS-10382 following fasting or fed administration
Time frame: Up to end of the study, approximately 1 month
clinical laboratory tests(complete blood count (CBC), urinalysis, blood chemistry, coagulation tests)
To evaluate the clinical laboratory tests (complete blood count (CBC), urinalysis, blood chemistry, coagulation tests) of HS-10382 following fasting or fed administration.
Time frame: Up to end of the study, approximately 1 month
12-lead electrocardiogram (include heart rate, PR, RR, QRS duration and QTcF)
To evaluate the 12-lead electrocardiogram(include heart rate, PR, RR, QRS duration and QTcF) of HS-10382 following fasting or fed administration.
Time frame: Up to end of the study, approximately 1 month
physical examination of HS-10382 following fasting or fed administration
To evaluate the abnormal of the physical examination (general inspection, head and neck, lymph nodes, chest, abdomen, spine and extremities, and neurological examination) of HS-10382 following fasting or fed administration.
Time frame: Up to end of the study, approximately 1 month
Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Embibatinib
Jiangsu Hansoh Pharmaceutical Co., Ltd. →